BR112023024064A2 - Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa - Google Patents

Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa

Info

Publication number
BR112023024064A2
BR112023024064A2 BR112023024064A BR112023024064A BR112023024064A2 BR 112023024064 A2 BR112023024064 A2 BR 112023024064A2 BR 112023024064 A BR112023024064 A BR 112023024064A BR 112023024064 A BR112023024064 A BR 112023024064A BR 112023024064 A2 BR112023024064 A2 BR 112023024064A2
Authority
BR
Brazil
Prior art keywords
tnf
antibodies
alpha
combination therapy
bowel disease
Prior art date
Application number
BR112023024064A
Other languages
English (en)
Portuguese (pt)
Inventor
Christopher O'brien
Jacqueline Perrigoue
Marion Vetter
Matthew Germinaro
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112023024064A2 publication Critical patent/BR112023024064A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112023024064A 2021-05-20 2022-05-19 Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa BR112023024064A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163191076P 2021-05-20 2021-05-20
PCT/IB2022/054701 WO2022243937A1 (en) 2021-05-20 2022-05-19 Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Publications (1)

Publication Number Publication Date
BR112023024064A2 true BR112023024064A2 (pt) 2024-01-30

Family

ID=81927398

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023024064A BR112023024064A2 (pt) 2021-05-20 2022-05-19 Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa

Country Status (11)

Country Link
US (1) US20220372129A1 (https=)
EP (1) EP4340875A1 (https=)
JP (1) JP2024520202A (https=)
KR (1) KR20240012469A (https=)
CN (1) CN118076385A (https=)
AU (1) AU2022276189A1 (https=)
BR (1) BR112023024064A2 (https=)
CA (1) CA3220618A1 (https=)
IL (1) IL308607A (https=)
MX (1) MX2023013788A (https=)
WO (1) WO2022243937A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
KR20230023663A (ko) 2020-05-21 2023-02-17 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법
WO2024228134A1 (en) * 2023-05-03 2024-11-07 Janssen Biotech, Inc. Method of treating ulcerative colitis with a combination of antibodies to il-23 and tnf alpha
EP4704895A1 (en) * 2023-05-03 2026-03-11 Janssen Biotech, Inc. Method of treating crohn's disease with a combination of antibodies to il-23 and tnf alpha
WO2025024723A1 (en) * 2023-07-26 2025-01-30 Sorriso Pharmaceuticals, Inc. Il-23 and tnf-alpha induction treatment for autoimmune and inflammatory disorders
WO2025076251A1 (en) * 2023-10-05 2025-04-10 Sorriso Pharmaceuticals, Inc. Dosages of il-23 and tnf-alpha inhibitors for use in autoimmune and inflammatory disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
AU2006265002B2 (en) 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
WO2017132457A1 (en) 2016-01-28 2017-08-03 Janssen Biotech, Inc. BISPECIFIC ANTI-TNF-α/IL-17A ANTIBODIES AND ANTI-TNF-α ANTIBODIES AND METHODS OF THEIR USE
EP3519049B1 (en) 2016-09-30 2025-12-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
TWI837532B (zh) * 2018-03-30 2024-04-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法
WO2020234834A1 (en) * 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
KR20230023663A (ko) * 2020-05-21 2023-02-17 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법

Also Published As

Publication number Publication date
AU2022276189A1 (en) 2024-01-18
EP4340875A1 (en) 2024-03-27
CN118076385A (zh) 2024-05-24
MX2023013788A (es) 2024-02-13
US20220372129A1 (en) 2022-11-24
IL308607A (en) 2024-01-01
CA3220618A1 (en) 2022-11-24
WO2022243937A1 (en) 2022-11-24
JP2024520202A (ja) 2024-05-22
KR20240012469A (ko) 2024-01-29

Similar Documents

Publication Publication Date Title
BR112021023295A2 (pt) Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
BR112023024064A2 (pt) Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
BR112022023489A2 (pt) Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
CL2022000057A1 (es) Métodos y productos para el tratamiento de trastornos gastrointestinales
CL2021001490A1 (es) Constructos de iarn modificados químicamente y usos de estos
MX2025010269A (es) Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de los mismos
EA202091673A1 (ru) Способ амплификации нуклеиновых кислот
BR112018071467A2 (pt) método de tratamento ou prevenção de patologias hepáticas
MX2018013727A (es) Dieta imitadora del ayuno (fmd) como un tratamiento inmunoregulador para enfermedades gastrointestinales autoinmunes/inflamatorias.
CL2017001960A1 (es) Métodos de tratamiento de enfermedades inflamatorias
BR112017014341A2 (pt) método e sistema para tratamento, estabilização, ou redução da gravidade ou progressão de uma doença de fígado gorduroso não alcoólica, e, composição.
MX2026000462A (es) Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de estos
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
BR112014008666A8 (pt) acelerando recuperação de músculo após a atrofia muscular ter induzido imobilização
BR112016029713A2 (pt) métodos para o tratamento de sobrepeso ou obesidade
BR112017014107A2 (pt) composição nutricional útil no tratamento de pacientes com ibd
MX382630B (es) Compuestos de pirazol disustituidos para el tratamiento de enfermedades.
BR112015013349A2 (pt) trieptanoína para o tratamento de deficiência de transportador de glicose 1
PH12019500422A1 (en) Methods and composition for the prediction of the activity of enzastaurin
BR112017006416A2 (pt) composição nutricional para meio gastrointestinal para proporcionar perfil aperfeiçoado de microbioma e metabólico
BR112017018758A2 (pt) alteração do metabolismo de esteroide para tratamento de doença dependente de esteroide
BR112023020669A2 (pt) Terapias de combinação para o tratamento de câncer
BR102016008872A8 (pt) método para produzir l-isoleucina
BR112014020095A8 (pt) Método para tratar doenças intestinais apresentando pelo menos um componente inflamatório
BR112020019624A8 (pt) Método para tratar a hipoglicemia pós-prandial